SCHEMBL3770950

SCHEMBL3770950

CC(=O)c1c(-c2ccccc2)[c]ncc1N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
ALDH1A1 P00352 6/20 0.45
MAPT P10636 2/20 0.45
ALOX15 P16050 1/20 0.45
NPSR1 Q6W5P4 2/20 0.45
TSHR P16473 2/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 4/20 0.42
MAPK1 P28482 1/20 0.42
MOK Q9UQ07 1/20 0.40
BRD4 O60885 1/20 0.40
POLB P06746 3/20 0.40
SCN9A Q15858 1/20 0.40
PDE4A P27815 1/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3754803 0.82 NCF1 (0.44) KMT2AMEN1GAAALDH1A1MAPT
SCHEMBL3763677 0.74 PDE4A (0.46) GAAALDH1A1MAPTNPSR1TSHR
SCHEMBL3996425 0.74 TSHR (0.49) KMT2AGAAALDH1A1MAPTALOX15
SCHEMBL3996329 0.71 CNR2 (0.42) ALDH1A1MAPTNPSR1TSHRHSD17B10
SCHEMBL3766048 0.70 TSHR (0.37) KMT2AGAAALDH1A1MAPTALOX15
SCHEMBL3751377 0.69 NPY5R (0.41) KMT2AMEN1GAAALDH1A1MAPT
SCHEMBL3754790 0.68 NPY5R (0.43) KMT2AGAAALDH1A1MAPTALOX15
SCHEMBL1286677 0.68 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1MAPTALOX15
SCHEMBL3766722 0.67 ALDH1A1 (0.52) KMT2AGAAALDH1A1TSHRSMN1; SMN2
SCHEMBL19287050 0.66 AKR1C3 (0.55) KMT2AGAAALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KMT2A 2175/4885MEN1 2762/4885GAA 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.